Showing results (1-10 of 17) with videos related to
Sort By:
Pageof 2
Clinical Lymphoma & Myeloma|September 1, 2009
Monoclonal gammopathy of undetermined significance: why identification of these patients and assessment of their skeletons is importantJames R Berenson, Ori YellinCurrent Opinion in Supportive and Palliative Care|August 8, 2008
New drugs in multiple myelomaJames R Berenson, Ori YellinDiagnostic Pathology|March 25, 2011
Using a powered bone marrow biopsy system results in shorter procedures, causes less residual pain to adult patients, and yields larger specimensJames R Berenson, Ori Yellin, Brent Blumenstein, et al.Annals of Hematology|September 3, 2010
A modified regimen of pegylated liposomal doxorubicin, bortezomib, and dexamethasone is effective and well tolerated in the treatment of relapsed or refractory multiple myelomaGabriel N Waterman, Ori Yellin, Regina A Swift, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 4, 2009
A phase I study of samarium lexidronam/bortezomib combination therapy for the treatment of relapsed or refractory multiple myelomaJames R Berenson, Ori Yellin, Ravi Patel, et al.Atherosclerosis|July 24, 2021
Alirocumab treatment and neurocognitive function according to the CANTAB scale in patients at increased cardiovascular risk: A prospective, randomized, placebo-controlled studyMatthew J Janik, Dorothea V Urbach, Elane van Nieuwenhuizen, et al.Annals of Hematology|May 9, 2008
Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-upJames R Berenson, Hank H Yang, Robert A Vescio, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2008
Zoledronic acid markedly improves bone mineral density for patients with monoclonal gammopathy of undetermined significance and bone lossJames R Berenson, Ori Yellin, Ralph V Boccia, et al.European Journal of Haematology|February 20, 2009
Bortezomib, ascorbic acid and melphalan (BAM) therapy for patients with newly diagnosed multiple myeloma: an effective and well-tolerated frontline regimenJames R Berenson, Ori Yellin, Donald Woytowitz, et al.Clinical Lymphoma, Myeloma & Leukemia|August 6, 2011
A retrospective study to evaluate the work-up and follow-up of patients with monoclonal gammopathy of undetermined significanceJames R Berenson, Ori Yellin, Albert Quiery, et al.Pageof 2